Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.56 |
| ▸ | DHODH | Q02127 | 5/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666215 | 0.93 | ADORA1 (0.51) | ADORA1DHODHADORA3 | |
| SCHEMBL4665259 | 0.92 | ADORA1 (0.51) | ADORA1DHODHFABP3FABP4ADORA3 | |
| SCHEMBL4668599 | 0.88 | ADORA1 (0.50) | ADORA1DHODHADORA3ADORA2AADORA2B | |
| SCHEMBL14600439 | 0.88 | ADORA1 (0.47) | ADORA1DHODH | |
| SCHEMBL14600229 | 0.87 | ADORA1 (0.45) | ADORA1DHODH | |
| SCHEMBL14600440 | 0.87 | ADORA1 (0.50) | ADORA1DHODHADORA3ADORA2AADORA2B | |
| SCHEMBL14600708 | 0.85 | ADORA1 (0.50) | ADORA1DHODHADORA3ADORA2AADORA2B | |
| SCHEMBL14600205 | 0.84 | ADORA1 (0.49) | ADORA1DHODHFABP3FABP4ADORA3 | |
| SCHEMBL14601007 | 0.83 | ADORA1 (0.48) | ADORA1DHODHADORA3ADORA2B | |
| SCHEMBL14600266 | 0.81 | ADORA1 (0.54) | ADORA1DHODHADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007027842-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER HEALTHCARE LLC (US) | 2007-03-08 | — | — | WO | disclosed |